Adaptive Mechanisms In GRown up ObeSity Study (AMIGROS)

Recruiting now

Conditions studied: Obesity, Type 2 Diabetes

In brief

The investigator recently showed that the glycan-binding adipokine galectin-1 increased during overfeeding and that galectin-1 independently could predict type 2 diabetes. Further, the molecules that induce insulin release in the fasting state when blood glucose is normal remain elusive. It is possible that galectin-1 is involved in adaptive mechanisms in adipose tissue in obese subjects.

Key facts

Study ID

NCT06065930

Run by

Vastra Gotaland Region

People needed

45

Starts

2023-05-05

Expected to finish

2028-12-31

Last updated by the study team

2023-10-04

Who can join

Age: 40 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women of age: 40.0 - 70.0 years
• BMI: 18.0 - 25.0 kg/m2 (lean subjects) and BMI 30.0 - 38.0 kg/m2 (Ob-IS and Ob-IR)
• Fasting insulin < 9.0 mU/l (lean and Ob-IS subjects) and fasting insulin > 9.0 mU/l (Ob-IR)
• Fasting glucose < 6.1 mmol/l
• Body temperature < 37.5°C
• First-degree relative with known T2D in Ob-IR
• Weight stable ± 5 kg < 3 months before screening
• Fluent in Swedish and can follow given instructions
• Consent given to participate

You may not qualify if…

• First-degree relative with known T2D in lean or Ob-IS subjects
• Alcohol intake > 10 units/week or known high alcohol intake < 10 years back in time
• Daily use of cigarettes or daily frequent use of smokeless tobacco not enabling the participant to suspend nicotine during a visit at the research center without getting abstinent
• Regular physical activity corresponding to Saltin-Gimby level 4
• Special diet eg Atkins or 5:2 for weight reduction. Vegetarian food accepted if duration > 1 year
• Impaired fasting glucose (IFG) (venous fasting plasma glucose 6.1-6.9 mmol/l)
• Type 2 diabetes according to ADA criteria
• Ongoing or previous ischemic heart disease, eg angina pectoris, unstable angina or previous myocardial infarction treated with platelet inhibitors or non vitamin-K oral anticoagulants
• Heart failure (NYHA II-IV) or cardiac arrhytmia that needs medical treatment
• Previous cerebral infarction or transitory ischemic episodes (TIA) treated with platelet inhibitors or other anticoagulants
• Peripheral arterial insufficiency eg claudication
• Hypertension >170/105 mmHg at screening or more than one class of drugs for treatment of known hypertension
• Lipid disorder defined as fasting serum triglycerides > 5.0 mmol/l or serum cholesterol > 7.5 mmol/l
• Hematologic diseases such as anemia not being substituted (Hb < 130 g/l in males and Hv < 120 g/l in females) or disease causing bleeding disorder
• Renal failure defined as absolute estimated glomerular filtration rate (eGFRcreatinine) < 60 ml/min/1.73 m2
• Hypothyroidism defined as TSH > 4.0 mIE/l and symptoms
• Liver disease e.g. hepatitis B, cirrhosis or conditions where AST or ALT are > 2 times UNL
• Systemic inflammatory disease e.g. rheumatoid arthritis, ulcerative cholitis or Chrons disease. Celiac disease, dyspepsia or IBS are excepted
• Chronic bronchitis or chronic obstructive pulmonary with disease symptoms
• Previous pancreatitis or other disease in pancreas that needs treatment
• Migraine elicited by stress
• Spinal insufficiency causing inconvenience lying in supine position during the study day
• Drug addiction interfering with the study procedures
• Psychiatric insufficiency interfering with the study procedures
• Medication with potential to affect adipose tissue metabolism that can not be stopped 10 days before the study days

Where it is running

• Gothia Forum CTC — Gothenburg, Region Vastra Gotaland, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.